Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2012 | 06:55pm CEST

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

 
   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
05:47p NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
05:31p NOVARTIS : receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acu..
04:31p NOVARTIS : to globally co-commercialise Amgens migraine drug
04/27 NOVARTIS : Patent Issued for Formulation Comprising Benzothiazolone Compound (US..
04/27 NOVARTIS : Allergan Expands Leading Research & Development NASH Program with Nov..
04/27 NOVARTIS : Patent Issued for Method for Making Contact Lenses (USPTO 9623614)
04/27 NOVARTIS : NIH study in NEJM shows Novartis drug eltrombopag as first-line thera..
04/27 NOVARTIS : Patent Issued for Process for Manufacturing an Ophthalmic Lens (USPTO..
04/27 NOVARTIS : Patent Issued for Process for Preparing Intermediates Useful in the M..
04/27 NOVARTIS : Patent Issued for Pharmaceutical Composition (USPTO 9622975)
More news
Sector news : Pharmaceuticals - NEC
05:59pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
02:37pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:04a FDA OKs Novartis' leukemia med Rydapt
04/27 BRISTOL-MYERS SQUIBB : Becoming An Increasingly Attractive Target
04/27 Amgen's Q1 Shows Challenges And Growth Opportunities Aplenty
04/27 G1 Therapeutics Seeks $115 Million IPO
04/27 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 28, 2017
Advertisement
Financials ($)
Sales 2017 48 401 M
EBIT 2017 12 341 M
Net income 2017 7 465 M
Debt 2017 14 141 M
Yield 2017 3,65%
P/E ratio 2017 22,62
P/E ratio 2018 19,91
EV / Sales 2017 4,50x
EV / Sales 2018 4,30x
Capitalization 203 449 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 79,7 $
Spread / Average Target 3,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.77%203 449
JOHNSON & JOHNSON7.40%335 446
ROCHE HOLDING LTD.10.83%225 921
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
SANOFI11.79%120 647
More Results